NCT02221492View on ClinicalTrials.gov

Plerixafor Plus Granulocyte Colony-Stimulating Factor For Mobilization And Collection Of Peripheral Hematopoietic Stem Cells In Japanese Participants With Non-Hodgkin Lymphoma

PHASE2CompletedINTERVENTIONAL
Enrollment

32

Participants

Timeline

Start Date

November 30, 2014

Primary Completion Date

March 31, 2016

Study Completion Date

March 31, 2016

Conditions
Lymphoma
Interventions
DRUG

plerixafor GZ316455

Pharmaceutical form:vial Route of administration: subcutaneous injection

DRUG

Filgrastim

Pharmaceutical form:vial Route of administration: subcutaneous injection

Trial Locations (12)

Unknown

Investigational Site Number 392005, Chiba

Investigational Site Number 392011, Fukuoka

Investigational Site Number 392014, Fukuyama-Shi

Investigational Site Number 392010, Hamamatsu

Investigational Site Number 392006, Kamogawa-Shi

Investigational Site Number 392003, Kobe

Investigational Site Number 392008, Kurashiki-Shi

Investigational Site Number 392015, Ota-Shi

Investigational Site Number 392004, Sapporo

Investigational Site Number 392001, Shibuya-Ku

Investigational Site Number 392009, Suwa-Shi

Investigational Site Number 392007, Toyohashi

All Listed Sponsors
lead

Genzyme, a Sanofi Company

INDUSTRY

NCT02221492 - Plerixafor Plus Granulocyte Colony-Stimulating Factor For Mobilization And Collection Of Peripheral Hematopoietic Stem Cells In Japanese Participants With Non-Hodgkin Lymphoma | Biotech Hunter | Biotech Hunter